Neurotech International Ltd. ( (AU:NTI) ) has issued an announcement.
Neurotech International Ltd announced its participation in the NWR Virtual Healthcare Conference, where CEO Dr. Anthony Filippis will present. This event provides an opportunity for the company to showcase its advancements in pediatric neurological disorder treatments, particularly its NTI164 drug formulation, which has demonstrated significant therapeutic potential in clinical trials. The presentation is expected to enhance Neurotech’s visibility and potentially attract interest from investors and stakeholders in the biopharmaceutical sector.
More about Neurotech International Ltd.
Neurotech International Limited is a clinical-stage biopharmaceutical development company focused predominantly on pediatric neurological disorders. The company is developing a broad-spectrum oral cannabinoid drug therapy called NTI164, which has shown clinically meaningful and statistically significant benefits in trials for Autism Spectrum Disorder (ASD), PANDAS/PANS, and Rett Syndrome. Neurotech has also received clearance for a Phase I/II clinical trial in spastic cerebral palsy.
YTD Price Performance: -47.27%
Average Trading Volume: 497,700
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$30.22M
For an in-depth examination of NTI stock, go to TipRanks’ Stock Analysis page.